Investing is fundamentally about growing wealth through capital appreciation and dividends. But what if I told you that there’s more to it? Surprised? Your investments could also come with added perks such as discounts or exclusive offers on products. For many shareholders, these benefits are the icing on the cake, offering a little extra beyond the usual capital gains and dividends.
Beyond Dividends: The rise of shareholder perks
One company that comes to mind when discussing shareholder perks is Indian Hotels Company Limited (IHCL), known for its iconic Taj hotel brand and a part of the prestigious Tata Group. On their official website, under the ‘Offers’ section, you’ll find special deals for IHCL shareholders. In September, Trident Ltd, the flagship company of the Punjab-based Trident Group, offered a festive season discount: a special 40 per cent discount voucher for its shareholders. This voucher could be redeemed on their e-commerce platform, myTrident, which offers a variety of products including bedsheets, towels, bathrobes, rugs, and more.
From Diamonds to AI? A new penny stock enters the game
A lesser-known company, Deep Diamond India, priced below Rs 10, has recently created a buzz with intriguing perks for its shareholders.
But before we come to that, here’s more on the company. As per its own website, the company states that it is a “a pharmaceutical company that focuses on developing and marketing innovative drugs and therapies to address unmet medical needs.” Interestingly, the company began as a manufacturer and seller of gold and diamond-studded jewelry, which it continues to pursue. The pharmaceutical business, which is garnering all the attention, is a recent diversification.
So, why is the company in the news?
Deep Diamond is providing a complimentary first health scan to all its registered shareholders. In a press release, Deep Diamond India announced, “As a gesture of gratitude for continued trust and support, we will extend a ‘complimentary first health scan’ to all registered shareholders.” Why was this announcement made? It was part of the launch of their new initiative – Deep Health India AI.
Deep Health India AI is a cutting-edge digital health initiative, featuring an intelligent camera-based wellness platform that uses facial-scan technology to provide real-time health insights. The platform leverages advanced computer vision and AI to analyse key wellness parameters, including heart rate, breathing rate, blood pressure, stress index, and oxygen saturation through a simple 60-second face scan. The technology is non-invasive, contactless, and can be accessed via any smartphone camera, enabling instant health feedback without the need for medical instruments or laboratory visits.
In their press release, the company highlighted that “The technology behind Deep Health India AI has been developed in collaboration with a global SDK partner specialising in AI-based physiological analysis, ensuring international-grade precision.” The platform will be available to the public on November 25, 2025, following its initial rollout to shareholders.
With the launch of Deep Health India AI, the company is making its mark in the digital wellness domain. After the public release, users will be able to access the platform with flexible pricing options, including Rs 35 for a single scan, Rs 75 for a pack of three scans, and subscription plans for frequent users.
Health perks and upper circuits: The stock performance
Turning to Deep Diamond India’s stock performance, the company has been hitting back-to-back upper circuits over the last three trading sessions. The stock has delivered multibagger returns of 126.5 per cent in the last three months. In the last six months the stock price has gained 104.3 per cent.
Deep Diamond 5-Yr Price Chart
This multibagger AI stock, priced below Rs 10, is offering additional perks for its shareholders. However, while the perks may add an attractive dimension to the investment, it’s important to remember that investing based solely on perks is not advisable.
In the case of Deep Diamond, one needs to also factor two more risks.
First, is that the pharmaceutical/health business is a recent diversification and the company therefore does not have a track record.
Second, this is a microcap company and therefore the risks associated with such companies in general are far greater than in the case of large, widely followed and tracked companies.
As always, a proper due diligence process should be undertaken before investing in any stock.
Disclaimer: The article is for informational purposes only and not investment advice.
Dalal Street Investment Journal (DSIJ) is India’s most trusted financial media
company, providing expert stock recommendations, market insights, and wealth-
building strategies for nearly four decades. To know more about DSIJ, visit here.
The website managers, its employee(s), and contributors/writers/authors of articles have or may have an outstanding buy or sell position or holding in the securities, options on securities or other related investments of issuers and/or companies discussed therein. The content of the articles and the interpretation of data are solely the personal views of the contributors/ writers/authors. Investors must make their own investment decisions based on their specific objectives, resources and only after consulting such independent advisors as may be necessary.